Integra LifeSciences reported a 2.4% increase in first-quarter 2026 revenues to $391.9 million, driven by strong demand in tissue reconstruction and neurosurgery products. Adjusted earnings per share rose to $0.54 from $0.41 last year, while GAAP net loss narrowed significantly. The company reaffirmed its full-year revenue guidance of $1.662-$1.702 billion and raised adjusted EPS guidance to $2.40-$2.50, citing improved operational execution and supply reliability. New CEO Stuart Essig highlighted progress in manufacturing and product launches, with confidence in meeting full-year targets.
CRCAM Alpes Provence has published its financial report as of June 30, 2026. The document is accessible on their official website and has been submitted to the French financial regulator, the Autorité des Marchés Financiers. This release ensures tran...
Between July 20 and July 24, 2026, Capgemini executed a buyback of 68,613 of its own shares at an average price of €91.59 per share. This transaction is part of the company's ongoing efforts to manage its capital structure and potentially enhance sha...
Commvault Systems reported strong Q1 2026 results, surpassing earnings per share and revenue estimates with EPS of $1.42 and revenue of $314.13 million. Subscription-based services drove growth, with subscription ARR up 22% to $1.05 billion and SaaS ...
Visa Inc. is set to report strong year-over-year growth in earnings per share and revenue, with analysts optimistic and maintaining Buy ratings. The company forecasts earnings of $3.23 per share on $11.40 billion revenue, up from $2.98 per share and ...
Block & Leviton LLP is investigating T1 Energy for potential securities law violations following the company's announcement of a 20% increase in capital expenditures and delays in its solar-cell project. The investigation centers on whether T1 Energy...
